On December 23, 2021, Shanghai Bio-heart Biological Technology Co., Ltd. (“Bioheart” or M88 Game “Company”) offered 23,937,000 H shares globally at M88 Game price of HK$ 21.25 per share and was successfully listed on M88 Game Hong Kong Stock Exchange.

Bioheart is a leading manufacturer of interventional cardiovascular devices in China. It focuses on two M88 Gamerapies, bioresorbable scaffolds (BRS) and renal denervation (RDN) to address M88 Game medical needs of Chinese patients in M88 Game treatment of coronary and peripheral artery disease and uncontrolled hypertension. JunHe acted as M88 Game IP lawyer for Bioheart when M88 Game Company was preparing for M88 Game IPO and assisted it in carrying out IP due diligence. JunHe provided quality, rigorous and effective legal services and helped M88 Game Company identify M88 Game risks associated with patent-related intellectual property.

M88 Game IP due diligence conducted for M88 Game IPO of Bioheart involved not only a comprehensive analysis of M88 Game intellectual property owned by M88 Game Company, but also a FTO analysis on M88 Game Company’s core products both in China and in some foreign countries. Through clear communication and cooperation with foreign law firms, JunHe successfully helped M88 Game Company identify and prevent patent-related risks associated with its core products in certain regions. JunHe was unanimously affirmed and highly trusted by M88 Game Company due to M88 Game team’s thorough work and professional services.

M88 Game leading partners of this project were Dr.WANG, Zhaohui (Zoe) , M88 Malaysia 于君合上海分所执业。andM88 Game 君合法评,君合人文,京公网安备11010102005423号 .